ProCE Banner Activity

DESTINY-Lung02: Interim Results With Trastuzumab Deruxtecan (T-DXd) in Patients With Previously Treated HER2-Mutated Metastatic NSCLC

Slideset Download
Conference Coverage
Interim analyses from the phase II DESTINY-Lung02 trial showed clinically meaningful responses and no new safety concerns with T-DXd 5.4 mg/kg in patients with HER2-mutant NSCLC who had received at least 1 previous line of therapy.

Released: September 26, 2022

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BMS

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp